Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Clinical Genitourinary Cancer|February 9, 2013
Serum M65 as a biomarker for metastatic renal cell carcinomaIbrahim Yildiz, Fatma Sen, Leyla Kilic, et al.
Expert Review of Anticancer Therapy|August 23, 2016
Renal cell cancer: overview of the current therapeutic landscapeMustafa Erman, Mustafa Benekli, Mert Basaran, et al.
The Tohoku Journal of Experimental Medicine|November 7, 2007
Clinical outcome of rhabdomyosarcoma in adolescent and adult patients: single center experience from TurkeyZeki Ustuner, Mert Basaran, Yavuz Dizdar, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|October 19, 2014
Diagnostic value of serum M30 and M65 in patients with nasopharyngeal carcinomaFatma Sen, Ibrahim Yildiz, Hatice Odabas, et al.
Clinical Nuclear Medicine|October 16, 2023
Radioligand Therapy With 177 Lu-PSMA-I&T in Patients With Metastatic Prostate Cancer : Oncological Outcomes and Toxicity ProfileMehmet Onur Demirkol, Barış Esen, Hülya Seymen, et al.
Urology|January 1, 2013
Safety of everolimus by treatment duration in patients with advanced renal cell cancer in an expanded access programAlfonsus J M van den Eertwegh, Pierre Karakiewicz, Sevil Bavbek, et al.
Tumori|July 22, 2017
Prognostic factors for survival in metastatic renal cell carcinoma patients with brain metastases receiving targeted therapyIbrahim Yildiz, Ahmet Bilici, Nuri Karadurmuş, et al.
The Lancet. Oncology|June 8, 2013
Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trialIan F Tannock, Karim Fizazi, Sergey Ivanov, et al.
Japanese Journal of Clinical Oncology|January 25, 2024
Beyond traditional therapies: clinical significance of complex molecular profiling in patients with advanced solid tumours-results from a Turkish multi-centre studyOmer Fatih Olmez, Ahmet Bilici, Ozlem Er, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 23, 2014
Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinomaRobert J Motzer, Carlos H Barrios, Tae Min Kim, et al.
Pageof 4